Wire · opportunities
Tam-Peli Extends Survival to 13.3 Months in Relapsed Small-Cell Lung Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
The phase III TAISHAN-302 trial found tambotatug pelitecan (Tam-Peli) significantly extends median overall survival to 13.3 months versus 9.4 months with topotecan in relapsed small-cell lung cancer, with a better safety profile and progression-free survival. The trial was conducted in China and results position Tam-Peli as a strong second-line treatment candidate.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Biotech founders in oncology should ready for a new competitive standard in second-line small-cell lung cancer driven by Tam-Peli; regulatory filings in China offer a rapid market entry challenge and a chance to define SCLC treatment globally.
◆ Coverage
1 source · 14 Sep 2026
◆ Related on Wire
◆ Topics